EQL PHARMA AB (F:7JK) — Market Cap & Net Worth
Market Cap & Net Worth: EQL PHARMA AB (7JK)
EQL PHARMA AB (F:7JK) has a market capitalization of $59.21 Million (€50.64 Million) as of October 11, 2026. Listed on the F stock exchange, this Germany-based company holds position #21329 globally and #1907 in its home market, demonstrating a -1.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EQL PHARMA AB's stock price €1.93 by its total outstanding shares 29529610 (29.53 Million).
EQL PHARMA AB Market Cap History: 2021 to 2026
EQL PHARMA AB's market capitalization history from 2021 to 2026. Data shows change from $124.97 Million to $66.77 Million (-10.35% CAGR). Check 7JK stock price and chart for real-time trading data and today's change.
EQL PHARMA AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EQL PHARMA AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see EQL PHARMA AB operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.15x
EQL PHARMA AB's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.33x
EQL PHARMA AB's market cap is 5.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $90.80 Million | $409.75 Million | $31.55 Million | 0.22x | 2.88x |
| 2023 | $96.32 Million | $259.91 Million | $30.92 Million | 0.37x | 3.12x |
| 2024 | $234.76 Million | $264.17 Million | $22.70 Million | 0.89x | 10.34x |
| 2025 | $184.35 Million | $373.52 Million | $43.12 Million | 0.49x | 4.28x |
| 2026 | $66.77 Million | $432.66 Million | $12.54 Million | 0.15x | 5.33x |
Competitor Companies of 7JK by Market Capitalization
Companies near EQL PHARMA AB in the global market cap rankings as of October 11, 2026. See 7JK equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to EQL PHARMA AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #526 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #526 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
EQL PHARMA AB Historical Marketcap From 2021 to 2026
Between 2021 and today, EQL PHARMA AB's market cap moved from $124.97 Million to $ 66.77 Million, with a yearly change of -10.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €66.77 Million | -63.78% |
| 2025 | €184.35 Million | -21.47% |
| 2024 | €234.76 Million | +143.73% |
| 2023 | €96.32 Million | +6.08% |
| 2022 | €90.80 Million | -27.35% |
| 2021 | €124.97 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 11th, 2026 the market cap of EQL PHARMA AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.21 Million USD |
| MoneyControl | $59.21 Million USD |
| MarketWatch | $59.21 Million USD |
| marketcap.company | $59.21 Million USD |
| Reuters | $59.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.